Research guides to the compounds we supply
What each compound is, what the laboratory literature studies, how identity and purity are verified, and where it stands with regulators. Written for researchers, not consumers.
Retatrutide
A reference guide to retatrutide for laboratory researchers: structure, receptor pharmacology, how purity is verified, handling, and regulatory status.
Read the guide →Peptides & skin biologyGHK-Cu
A reference guide to GHK-Cu, the copper-binding tripeptide: structure, what cell-culture research looks at, identity checks, storage and regulatory status.
Read the guide →Melanocortin researchMelanotan I & II
A reference guide to melanotan I and melanotan II, synthetic melanocortin peptides: structures, receptor pharmacology, identity checks and regulatory status.
Read the guide →Longevity & cognitiveSelank
A reference guide to Selank, a synthetic heptapeptide analogue of tuftsin: structure, what preclinical research examines, identity checks and regulatory status.
Read the guide →Latest from the blog
All articlesWhat Is Retatrutide? How the GIP, GLP-1 and Glucagon Triple Agonist Works
Retatrutide (LY3437943) is an investigational once-weekly peptide from Eli Lilly that activates three receptors at once: GIP, GLP-1 and glucagon. No regulator has approved it.
Retatrutide Clinical Trial Results: Phase 2 to the TRIUMPH Phase 3 Programme
Retatrutide has two Phase 2 trials behind it and, by Lilly’s count, six positive Phase 3 studies: four in the TRIUMPH programme and two in the TRANSCEND diabetes programme.
Retatrutide Side Effects: What the Clinical Trials Actually Reported
In Lilly’s trials, retatrutide’s adverse events are mostly gastrointestinal and rise with dose. The one signal that stands apart from comparable drugs is dysaesthesia (reported as dysesthesia in Lilly’s US releases), an abnormal skin sensation.